Integra LifeSciences (NASDAQ:IART) Updates Q1 2025 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) updated its first quarter 2025 earnings guidance on Tuesday. The company provided earnings per share guidance of 0.400-0.450 for the period, compared to the consensus earnings per share estimate of 0.560. The company issued revenue guidance of $375.0 million-$385.0 million, compared to the consensus revenue estimate of $411.7 million. Integra LifeSciences also updated its FY 2025 guidance to 2.410-2.510 EPS.

Integra LifeSciences Trading Up 12.1 %

Shares of Integra LifeSciences stock opened at $24.72 on Wednesday. Integra LifeSciences has a 1 year low of $16.81 and a 1 year high of $44.91. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. The business has a 50 day moving average price of $23.71 and a 200 day moving average price of $21.83. The company has a market capitalization of $1.91 billion, a P/E ratio of -274.64, a P/E/G ratio of 0.73 and a beta of 1.17.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.12. The company had revenue of $442.65 million during the quarter, compared to analysts’ expectations of $445.15 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The business’s revenue for the quarter was up 11.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.89 earnings per share. Sell-side analysts anticipate that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

IART has been the subject of a number of recent research reports. Citigroup lifted their price target on shares of Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a report on Tuesday, November 5th. Morgan Stanley began coverage on shares of Integra LifeSciences in a research note on Monday, December 2nd. They issued an “underweight” rating and a $20.00 target price for the company. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $23.00.

Insider Activity at Integra LifeSciences

In other Integra LifeSciences news, EVP Michael J. Mcbreen sold 1,700 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $24.16, for a total transaction of $41,072.00. Following the completion of the sale, the executive vice president now owns 56,182 shares of the company’s stock, valued at approximately $1,357,357.12. The trade was a 2.94 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.10% of the stock is owned by insiders.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.